Opsynvi (Macitentan/Tadalafil) Patent Expiration, LOE Window & CMS Spending
Opsynvi (Macitentan/Tadalafil) by Johnson & Johnson: FDA Orange Book core substance LOE 2026-06-05 (last listed 2031-09-22), 0 AB generics, $30.1M 2024 CMS Part D & Medicaid spend, and $12,635 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N218490 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-06-05 |
| Last Listed Patent or Exclusivity Date | 2031-09-22 |
| Orange Book Patents (*PED Extensions) | 6 patents (3 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $30.1M |
| 2024 Medicare Part D Spend | $24.5M |
| 2024 Medicaid Spend | $5.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($12,635 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.